NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BlueSphere Bio

BlueSphere Bio

Private
Pittsburgh, PennsylvaniaHealthcare & Life Scienceshttps://bluespherebio.com/

Last Round

Series B

Aug 19, 2021

Total Funding Raised

$115M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

BlueSphere Bio is a biotechnology company that develops personalized T-cell therapies for cancer treatment using its proprietary TCXpress and NeoXPress platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

TCR T-cell therapycell therapyTCR discovery platformcancer immunotherapyleukemia therapyadoptive cell therapyneoantigen discoveryclinical-stage biotechhematologic malignanciesprecision medicinehigh-throughput screeningsolid tumor therapyacute myeloid leukemiaNPM1 mutationHA-1 antigen

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BlueSphere Bio Comparables

Compare BlueSphere Bio with similar companies based on industry and business-model similarity.

BlueSphere Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
T-Therapeutics
83%
3T Biosciences
82%
Enara Bio
80%

BlueSphere Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 19, 2021
Series AOct 1, 2018

Key People

Founding team and executive leadership

Chris Caracciolo

Chief Financial Officer

Executive Team

BlueSphere Bio Investors

Notable investors and investment history

BlueSphere Bio investors
InvestorRounds
UPMC EnterprisesSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 28, 5.6x the trailing average.

  • Feb 1, 2026

    Monthly visitors grew 50% MoM, reaching 2.7K.

BlueSphere Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BlueSphere Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BlueSphere Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersPittsburgh, Pennsylvania
Employee Range28
Year Founded2017
Last FundingAug 19, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.